A real-world trial of ILUVIEN® (fluocinolone acetonide) in patients with chronic diabetic macular edema (DME)

Trial Profile

A real-world trial of ILUVIEN® (fluocinolone acetonide) in patients with chronic diabetic macular edema (DME)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms RETRO-IDEAL
  • Most Recent Events

    • 08 Sep 2017 New trial record
    • 05 Sep 2017 According to an Alimera Sciences media release, results from this trial will be presented during the 17th European Society of Retina Specialists Congress (EURETINA) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top